Matthew Meselson

Matthew S. Meselson waited quietly in the car while female associates handled the delicate work of questioning families of people who had died of anthrax. The scientist had charmed, wrangled, and nagged politicians on two continents from 1979 to 1992 for permission to probe a strange outbreak of the disease in the Soviet city of Sverdlovsk 1979. But just days before Meselson boarded a plane for Moscow to conduct the interviews, former President Boris Yeltsin, a Sverdlovsk official during the out

Written byPeg Brickley
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Meselson, now Thomas Dudley Cabot professor of the natural sciences at Harvard University, persisted in investigating the largest-known epidemic of deadly human inhalational anthrax. "We had no idea what would happen when we knocked on the door and said we want to talk about anthrax," he says. "Would [the female investigators] be kicked out? Nobody kicked them out. Everybody gave them tea and cake." The Meselson team members published their findings in 1994: The Soviet government had accidentally triggered the outbreak while developing biological weapons at a military microbiology facility in violation of an international agreement.

Now a trim, energetic man of 71, Meselson recounts the Sverdlovsk history as he fields phone calls from U.S. News and World Report, The New York Times, and from television news reporters from Germany and Switzerland. All seek scientific explanations of Bacillus anthracis. With British chemist and activist Julian Perry Robinson, Meselson cochairs the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies